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Abstract 
The effects of MK-467, a peripherally acting 2-adrenoceptor antagonist, on the 
cardiopulmonary changes induced by dexmedetomidine, a specific and selective 2-
adrenoceptor agonist, were investigated in dogs. Plasma concentrations of both 
drugs were also quantified, along with influence of MK-467 on the quality of clinical 
sedation achieved with dexmedetomidine. 
   The main focus of this study was on preventing or attenuating the cardiovascular 
effects of dexmedetomidine. The effects of three different doses of MK-467, 
administered simultaneously with the agonist, on the main hemodynamic parameters 
were evaluated and compared with a single dose of both dexmedetomidine and MK-
467 administered alone. Respiratory effects were evaluated with arterial blood 
gases, and indices such as oxygen delivery were calculated. The pharmacokinetic 
interaction between the two drugs was evaluated in vivo and general information on 
the disposition of intravenously administered MK-467 in dogs was produced. The 
degree of clinical sedation was subjectively assessed during the studies. The effect 
of MK-467 on the quality of reversal of dexmedetomidine-induced sedation with 
atipamezole was also determined. 
   MK-467 dose-dependently reduced or prevented all relevant cardiovascular 
changes induced by dexmedetomidine. The heart rate, arterial and central venous 
blood pressure, cardiac index, systemic vascular resistance and oxygen delivery 
remained within acceptable physiological limits throughout the observational period 
with all doses of MK-467 administered with the agonist. Moderate hypotension was 
seen with the highest dose of MK-467. No significant differences in respiratory 
function were observed between treatments. MK-467, when administered alone, 
induced sinus tachycardia along with increases in the cardiac index and reductions 
in systemic vascular resistance. Arterial blood pressures remained unchanged.  
   The degree of clinical sedation was reduced by MK-467, most likely by increasing 
the disposition of dexmedetomidine, which led to lower plasma concentrations of the 
agonist. However, the differences in clinical sedation were minor. MK-467 did not 
interfere with the ability of atipamezole to reverse dexmedetomidine-induced 
sedation. 
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Abbreviations 
ADH antidiuretic hormone 
ATP adenosine triphosphate 
AUC area under curve 
BBB blood–brain barrier 
cGMP cyclic guanosine 3’, 5’ monophosphate 
CI cardiac index 
CI95 95% confidence interval 
CNS central nervous system 
CO cardiac output 
CSS composite sedation score 
CVP central venous pressure 
DAP diastolic arterial pressure 
DO2 oxygen delivery 
ECG electrocardiography 
GABA gamma-amino butyric acid 
HR heart rate 
IM intramuscular 
IUPAC international union of pure and applied chemistry 
IV intravenous 
MAC  minimal alveolar concentration 
MAP  mean arterial pressure 
m/z mass-to-charge ratio 
NLC nucleus locus coeruleus 
N2O nitrous oxide 
P(A-a)O2 alveolar-to-arterial oxygen partial pressure difference 
PaCO2 arterial partial pressure of carbon dioxide 
PaO2 arterial partial pressure of oxygen 
SaO2 arterial hemoglobin saturation percent 
SAP systolic arterial pressure 
SD standard deviation 
SVR systemic vascular resistance 
Vd volume of distribution 
Introduction 
9
1. Introduction 
Dexmedetomidine is a potent and specific alpha2-adrenoceptor agonist that is widely 
used in small animal practice as a sedative and/or pre-anesthetic drug. Its use is 
currently limited in compromised animals due to characteristic effects on the 
cardiovascular system, including hypertension, bradycardia, and consequent 
decreases in the cardiac index and tissue oxygen delivery. When necessary, both 
the central and peripheral outcomes can be reversed with atipamezole, a specific 
alpha2-adrenoceptor antagonist. 
   MK-467 (also known as L-659,066) is an alpha2-adrenoceptor antagonist that is 
thought not to cross the mammalian blood–brain barrier, limiting its 
pharmacodynamics to peripheral organ systems. MK-467 has gained increasing 
interest due to its potential for preventing or attenuating the peripheral hemodynamic 
effects of both medetomidine and dexmedetomidine, while allowing for the central 
properties of the agonist drugs. 
   Thus far, the agonist–antagonist combination has been preliminarily studied in 
dogs and sheep, without reported adverse effects and showing promising stability of 
cardiovascular function. 
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2. Review of the literature 
2.1 Adrenergic receptors
Adrenergic receptors are an essential part of the autonomic nervous system, 
mediating their main physiological effects via adrenaline and noradrenaline.  
Adrenoceptors are classified into types,  and , depending on their specific location 
and action (Ahlquist, 1948). The -adrenoceptors are then further divided into types 
1 and  2 according to their specific physiological properties along with varying 
affinities to both endo- and exogenous ligands. Type 1-adrenoceptors mediating the 
effects of catecholamines are mainly located on the post-synaptic membrane 
whereas the role of the mostly pre-synaptically located 2-adrenoceptors is one of 
inhibition, as their activation leads to decreased excretion of noradrenaline into the 
synaptic space (Langer, 1974; Berthelsen and Pettinger, 1977; Vargas and Gorman, 
1995).
   However, a significant subpopulation of peripheral 2-adrenoceptors is involved, for 
instance, in regulating the vasomotor tone of vessels, thus influencing blood 
pressure (Piascik et al., 1996; Gyires et al., 2009). Genetic polymorphism both 
across and within these subpopulations has also been reported (Muskat et al., 2005; 
Kurnik et al., 2006). Thus, the net effect of any agonist or antagonist affecting the 
general population of 2-adrenoceptors is characterized by a complex series of 
events within both the central nervous system (CNS) and the peripheral organ 
systems (Khan et al., 1999; Kamabayashi and Maze, 2000; Murrell and 
Hellebrekers, 2005). 
2.2 2-adrenoceptors within the central nervous system 
In the mammalian nervous system, the nucleus locus coeruleus (NLC) is an 
epicenter of noradrenergic pathways affecting both cortical activity and spinal 
modulation of selected afferent and efferent nerve fibers (Figure 1). A high 
prevalence of 2A-adrenoceptors is found within the NLC, and they are thought to be 
responsible for mediating much of the sedative and antinociceptive effects of 2-
adrenoceptor agonists such as dexmedetomidine (Correa-Sales et al., 1992a; 
Scheinin and Schwinn, 1992). High densities of 2A-adrenoceptors are also found in 
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the descending pathways within the spinal column, where they modulate nociceptive 
stimuli and interactions with opioids (Calzada and Artinano, 2001; Fairbanks et al., 
2009). This subreceptor type is also likely to affect central control of vasomotor tone 
and is thought to mediate both hypotension and bradycardia in the presence of 
agonists, although the specific location of the 2-adrenoceptors responsible for this 
effect remains unclear (Link et al., 1996; MacMillan et al., 1996; Nassar and Abdel-
Rahman, 2006).  
NLC
Figure 1. The nucleus locus coeruleus (NLC) within the mammalian CNS. 
   The 2C-adrenoceptors, which are found in terminals of afferent primary sensory 
neurons, play a role in both mediating and modulating antinociception. This receptor 
subtype is involved in a synergistic interaction with opioids in producing analgesia at 
the spinal level (Fairbanks et al., 2009). The 2B-adrenoceptors are scarce within the 
adult CNS and are limited in rats to the thalamic region (Scheinin et al., 1994), 
although they have been implicated in modulating N20 mediated nociception in mice 
in concert with the 2A-adrenoceptors (Guo et al., 1999; Sawamura et al., 2000). 
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2.3 Imidazoline receptors within the central nervous system 
Some of the central hypotensive effects of 2-adrenoceptor agonists have been 
attributed to non-adrenergic receptors located in the nucleus reticularis lateralis 
found in the ventrolateral medulla that specifically recognize an imidazoline-ring 
structure found, for instance, in dexmedetomidine and clonidine (Bousquet et al., 
1984; Khan et al., 1999). Of the two isolated subtypes, I1 is mainly responsible for 
central control of blood pressure (Ernsberger et al., 1998a; Edwards et al., 2011). 
Imidazoline receptor agonists act as antihypertensives and are also thought to be 
more important than 2-adrenoceptors in the central inhibition of catecholamine-
induced dysrhythmias (Kamibayashi et al., 1995b; Mammoto et al., 1996). 
Imidazoline receptor agonists have not been shown to cause either sedation or 
antinociception (Khan et al., 1999; Prichard and Graham, 2000). In essence, central 
imidazoline receptors seem to have a complimentary effect with 2-adrenoceptors. 
2.4 Peripheral 2-adrenoceptors 
2.4.1 The 2B-adrenoceptors 
This subpopulation, which like other 2-adrenoceptors is activated by both 
noradrenaline and adrenaline, mediates the typical vasoconstrictive effects induced 
by 2-adrenoceptor agonists such as dexmedetomidine (Piascik et al., 1996; Link et 
al., 1996). This increase in arterial vasomotor tone is mediated via extrajunctional, 
postsynaptic receptors located in vascular smooth muscle, and the receptor-specific 
signal mechanism is linked with a voltage-gated Ca2+-channel allowing the 
translocation of extracellular calcium (Ruffolo, 1985). As of late, the inhibition of ATP-
sensitive potassium channels has been proposed as the underlying primary effector 
mechanism initiating the signaling cascade of dexmedetomidine-induced peripheral 
vasoconstriction in rat aortic cell preparations (Kawano et al., 2012). Nevertheless, 
the Ca2+-channel antagonists nifedipine and isradipine normalized the increases in 
mean arterial pressure after dexmedetomidine administration in isoflurane-
anesthetized dogs (Bloor et al., 1992a; Roekaerts et al., 1997). The 2B-
adrenoceptors are thought to preferentially mediate arterial rather than venous 
contraction in the presence of agonists (Link et al., 1996; Philipp and Hein, 2004). 
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2.4.2 The 2A- and 2C-adrenoceptors 
The distribution and activity of vascular 2-adrenoceptors varies between species, 
and their prevalence presumably differs based on the vascular type and location. In 
the dog, Polonia et al. (1985) postulated that while the predominant adrenoceptor 
population mediating vasoconstriction in canine arteries is type 1, the net effect from 
2-adrenoceptors is more important within the venous vasculature. Further work by 
MacLennan et al. (1997) suggested that postsynaptic 2A-adrenoceptors in the 
canine saphenous vein were largely responsible for the contractile effects of -
adrenoceptor agonists. Nimodipine, another Ca2+-channel antagonist, inhibited 2-
adrenoceptor agonist-induced contraction of vascular smooth muscle in the canine 
saphenous vein model, while it had little effect on 1-adrenoceptor agonists (Cooke 
et al., 1985). 
   Peripheral 2A-adrenoceptors, as well as the 2C-adrenoreceptors, have also been 
implicated in modulating hyperalgesia after experimental tissue injury (Fairbanks et 
al., 2002; Tomic et al., 2007). Furthermore, the 2A-adrenoceptors have been 
suggested to enhance the peripheral action of local anesthetics (Yoshitomi et al., 
2008). The role of 2C-adrenoceptors in mediating arterial or venous vasoconstriction 
in dogs remains unclear. 
2.5 Peripheral imidazoline receptors 
The role of peripheral imidazoline receptors is controversial. Both I1 and I2 subtype 
receptors have been located within various organ systems, such as hepatic, renal, 
adrenal medullar, adipose and peripheral neuronal tissue (Ernsberger et al., 1998a; 
Khan et al., 1999). While within the CNS I1 receptors seem to be restricted to 
neuronal plasma membranes, in the periphery the majority of I2 receptors are found, 
for instance, within mitochondrial membranes (Regunathan et al., 1993) 
Furthermore, unlike the central receptors, the peripheral I2 subtype is not linked with 
a G-protein, and monoamine oxidation inhibition has been suggested as the primary 
signaling mechanism (Ernsberger et al., 1998a). However, these imidazoline 
receptors are not without pharmacological effect, and whilst difficult to completely 
distinguish from the actions of the adrenoceptors, it has been suggested that their 
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action is in fact distinct from, or often even opposite to, the peripheral 2-
adrenoceptors (Ernsberger at al., 1998b). 
2.6 Dexmedetomidine 
Figure 2. Dexmedetomidine. 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole (IUPAC) 
Dexmedetomidine, a selective and specific 2-adrenoceptor agonist, is the 
dextroisomer of the racemic mixture, medetomidine (Aantaa et al., 1993; 
Kamibayashi and Maze, 2000). Medetomidine includes an equal concentration of 
levomedetomidine, the levoisomer thought to have little or no pharmacological 
activity in 2-adrenoceptors (Kuusela et al., 2001a). Structurally, dexmedetomidine is 
a chiral methylol derivative including an imidazoline-ring and has a molecular weight 
of 200.3. Dexmedetomidine is currently licensed for sedation in dogs, cats and 
humans. 
2.6.1 Cardiovascular effects of dexmedetomidine 
The cardiovascular outcome of dexmedetomidine in dogs is well described, although 
not yet completely elucidated. It is commonly agreed that the hemodynamic effects 
of dexmedetomidine are a result of the activation of both central and peripheral 2-
adrenoceptors, as dexmedetomidine is readily distributed across the blood–brain 
barrier. In dogs, marked vasoconstriction and hypertension are initially seen, 
followed almost immediately by baroreflex-mediated bradycardia (Bloor et al., 
1992a). Consequently, the cardiac index and oxygen delivery decrease as systemic 
vascular resistance and central venous pressure are increased (Flacke et al., 1993). 
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The following central sympatholysis and/or increase in parasympathetic tone leads to 
a reduction in systemic blood pressure as both the bradycardia and decrease in the 
cardiac index are sustained, suggestive of an inhibitory action on the baroreflex-
mediated autonomic ventricular-vascular coupling (Xu et al., 1998). On the other 
hand, indirect suppression of the canine myocardium mediated through reduced 
catecholamine availability has also been suggested (Flacke et al., 1993; Roekaerts 
et al., 1997). A direct inhibitory effect on the contractility of the canine myocardium 
seems unlikely (Flacke et al., 1992). In denervated dogs, different administration 
regimens (intravenous bolus/infusions) lead to typical cardiovascular changes that 
were readily antagonized by atipamezole (Flacke et al., 1990).  
   Coronary vasoconstriction has been reported in dogs after dexmedetomidine, 
although its clinical significance remains unclear (Schmeling et al., 1991; Flacke et 
al., 1993). In fact, dexmedetomidine reduced hemodynamic indices of myocardial 
oxygen demand to a similar extent as recorded with esmolol, a 1-adrenenoceptor 
antagonist, without actually reducing myocardial oxygen consumption (Willigers et 
al., 2004 and 2006). During experimentally induced myocardial ischemia in dogs, a 
dexmedetomidine infusion reduced the release of myocardial lactate when compared 
to saline, leading the authors to postulate that dexmedetomidine might have anti-
ischemic properties in the canine myocardium (Willigers et al., 2003). 
   Acute 2-adrenoceptor agonist-induced arrhythmias in dogs are characterized by 
the expected sinus bradycardia along with varying disturbances in sinoatrial and/or 
atrioventricular conductivity (Vainio and Palmu, 1989; Kramer et al., 1996). Kuusela 
et al. (2000 and 2001a) reported frequent 1st degree and occasional 2nd degree 
atrioventricular blocks accompanied by accentuated sinus arrhythmia and prolonged 
sinus pauses after both medetomidine and dexmedetomidine administration. 
Electrical abnormalities of ventricular origin have been infrequently reported. All 
changes in the electrocardiograms resolve spontaneously, and 24-hour Holter 
monitoring performed after medetomidine/dexmedetomidine sedation in healthy 
beagle dogs revealed no sustained arrhythmias (Kuusela et al., 2002). 
Dexmedetomidine has been shown to dose-dependently attenuate adrenaline-
induced arrhythmias in halothane-anesthetized dogs, although this effect seems to 
be central in origin and more dependent on imidazoline receptors rather than 2-
adrenoceptors (Hayashi et al., 1993; Kamibayashi et al., 1995a and b). On the other 
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hand, clinically used doses of medetomidine, with or without atipamezole 
administration, failed to produce a similar effect (Pettifer et al., 1996). 
   In chloralose/urethane or halothane/fentanyl-anesthetized dogs, increasing doses 
of dexmedetomidine produced slightly different hemodynamic effects, while in both 
groups the distribution of the remaining cardiac output, measured 15 minutes after 
drug administration, was better preserved in more vital organs than, for instance, the 
skin or spleen (Lawrence et al., 1996). In a laser Doppler study, intestinal and 
skeletal, but not renal cortical microvascular perfusion was reduced by intramuscular 
medetomidine in dogs anesthetized with isoflurane (Pypendop and Verstegen, 
2000). Premedication with intramuscular medetomidine increased the CNS uptake of 
a lipophilic tracer during brain perfusion imaging in healthy dogs, leading the authors 
to postulate that the central distribution of the tracer might have been enhanced as a 
consequence of a lower proportionate decrease in CNS perfusion when compared to 
peripheral tissues (Waelbers et al., 2011). Moreover, intravenous dexmedetomidine 
reduced cerebral oxygen transport during normoxia, but did not impair a hypoxia-
induced increase in cerebral blood flow in isoflurane-anesthetized dogs (McPherson 
et al., 1994). Although the central and peripheral effects on cardiovascular function 
have been difficult to distinguish, the peripheral hemodynamic effects seem to be 
accomplished with lower doses than the central ones in canines, with higher doses 
leading to the prolongation of both effects (Pypendop and Verstegen, 1998; Kuusela 
et al., 2000). 
2.6.2 Respiratory effects of dexmedetomidine 
A decreased respiratory rate is the most commonly reported finding with either 
medetomidine or dexmedetomidine in dogs, along with mild reductions in arterial 
oxygen tension (Vainio, 1989; Kramer et al., 1996; Ko et al., 1996; Kuusela et al., 
2000). Arterial carbon dioxide concentrations remain unaffected, although a reduced 
ventilatory response during hypercapnia has been reported for dexmedetomidine 
(Sabbe et al., 1994). Equipotent doses of medetomidine and dexmedetomidine 
produced similar alterations in arterial blood gas tensions (Kuusela et al., 2001a). 
However, when combined with opioids, significant hypoxemia and hypercapnia can 
occur (Ko et al., 1996; Raekallio et al., 2009). Interestingly, high doses of 
dexmedetomidine have also been described to increase minute ventilation in dogs, 
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an effect that was abolished by concurrent administration of isoflurane (Nguyen et 
al., 1992). 
2.6.3 Central effects of dexmedetomidine 
Dexmedetomidine induces a dose-dependent degree of sedation by inhibiting 
monoaminergic transmission (i.e. noradrenaline, serotonin and dopamine) within the 
CNS (Rabin et al., 1996; Millan et al., 2000; Lähdesmäki et al., 2003). A diversity of 
additional or contributing mechanisms, such as increased GABAergic activity, 
decreased glutamanergic neurotransmission and alterations in cerebellar cGMP 
activity, have also been suggested to participate in dexmedetomidine’s central 
mechanisms of action (Seidel et al., 1995; Vulliemoz et al., 1996; Huang and Hertz, 
2000; Chiu et al., 2011). While the specific effector mechanism varies between 
different 2-adrenoceptor subtypes and/or locations, cellular effects are produced via 
a G-protein-linked signaling mechanism (Kamibayashi and Maze, 2000). More 
specifically, dexmedetomidine yields its hypnotic action by altering the degree of 
phosphorylation of potassium channels via inhibition of the action of adenylate 
cyclase, thus hyperpolarizing the neuronal plasma membrane (Correa-Sales et al., 
1992b; Shirasaka et al., 2007). The consequent inhibition of the voltage-dependent 
Ca2+ channels is likely to be linked to the ultimate suppression of neurotransmitter 
release into the synaptic spaces (Hayashi and Maze, 1993; Chiu et al., 2011).  
   The main central antinociceptive action of dexmedetomidine is thought to be 
mediated via spinal 2-adrenoceptors located in the substantia gelatinosa within the 
dorsal horns of the spinal cord (Howe et al., 1983; Kuraishi et al., 1985; Hayashi et 
al., 1995). However, a supraspinal component via the NLC has also been suggested 
(Pertovaara et al., 1991; Guo et al., 1996). In fact, 2-adrenoceptor agonists have 
been reported to produce an analgesic action when administered parenterally, 
epidurally or intrathecally (Khan et al., 1999; Kamibayashi and Maze, 2000). 
   In dogs, both medetomidine and dexmedetomidine produce a dose-dependent 
degree of sedation after intravenous or intramuscular administration (Vainio, 1989; 
Sabbe et al., 1994). Furthermore, higher doses will prolong the sedative effects, 
while the intensity of the sedation is not increased further after a ceiling effect 
(Pypendop and Verstegen 1998; Kuusela et al., 2000). Studies on the analgesic 
effects of medetomidine and dexmedetomidine have yielded varying results in dogs, 
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probably due to the difficulties in differentiating between sedation and analgesia (i.e. 
perception and/or inhibition of a nociceptive pathway) within various experimental 
settings. Interestingly, van Oostrom et al. (2010) suggested that higher plasma 
concentrations of dexmedetomidine are necessary to attenuate a somatosensory 
than an auditory response in dogs.  
2.6.4. Other effects of dexmedetomidine 
Due to the wide distribution of different 2-adrenoceptors throughout the mammalian 
body, all relevant 2-adrenoceptor agonists produce a variety of pharmacological 
effects on different organ systems. One of the most relevant effects is pronounced 
diuresis, which is thought to be caused by inhibition of the antidiuretic hormone 
(Jackson et al., 1992; Saleh et al., 2005; Villela et al., 2005). The diuretic effect can 
be antagonized with atipamezole (Talukder et al., 2009). Medetomidine and 
dexmedetomidine have also been implicated in interfering with blood glucose 
homeostasis via insulin inhibition, an effect suggested to be mediated via the 2A-
adrenoceptors (Burton et al., 1997; Fagerholm et al., 2004). 
   Medetomidine and dexmedetomidine have also been shown to modulate 
physiological stress responses in dogs (Ko et al., 2000; Kuusela et al., 2003). 
Compared to saline, premedication with medetomidine blunted the elevations in 
blood adrenaline, noradrenaline, adrenocorticotropic hormone and insulin 
concentrations during ovariohysterectomy in dogs (Benson et al., 2000). 
Furthermore, blood catecholamine, but not beta-endorphin concentrations, were 
significantly lower with medetomidine than with acepromazine premedication during 
a similar study setting (Väisänen et al., 2002). In humans, dexmedetomidine has 
also been reported to decrease the temperature threshold of shivering (Talke et al., 
1997; Weant et al, 2010; Bajwa et al., 2012). 
2.6.5 Pharmacokinetics of dexmedetomidine 
The hemodynamic effects of dexmedetomidine have been suspected to influence its 
pharmacokinetic behavior (Salonen et al., 1995; Kuusela et al., 2000; Escobar et al., 
2012). Kuusela et al. (2000) separately examined the pharmacokinetics of both 
dexmedetomidine and levomedetomidine in dogs. After single IV doses of 10 and 20 
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μg/kg, steady-state Vd for dexmedetomidine remained below 1 L/kg compared to 
respective values above 2.5 L/kg for the levoisomer. Similarly, the clearance of 
dexmedetomidine was less than a third of that for levomedetomidine as the marked 
decrease in the cardiac output could logically influence plasma concentrations of the 
active dextroisomer (Dutta et al., 2000; Pypendop et al., 2012). Salonen et al. (1995) 
showed that administration of atipamezole increased the clearance of medetomidine 
in dogs, leading the authors to postulate that metabolism of the latter was influenced 
by changes in hepatic blood flow. On the other hand hepatic biotransformation, 
rather than the degree of liver perfusion, has been suggested as the rate-limiting 
step in the metabolic clearance of racemic medetomidine (Salonen et al., 1989). In 
two in vitro studies, a low rate of biotransformation by canine hepatocytes has been 
described for both medetomidine and dexmedetomidine (Kaivosaari et al., 2000; 
Duhamel et al., 2010). Overall, while some of these discrepancies in the 
pharmacokinetic behavior between the two enantiomers could be explained by 
differences in rates of their hepatic biotransformation, equipotent doses of racemic 
medetomidine and dexmedetomidine still produced comparably behaving plasma 
concentrations in dogs (Kuusela et al., 2000). The hepatic extraction ratio of 
dexmedetomidine has not been reported for dogs. 
2.7 MK-467 
Figure 3. MK-467. N-[2-[(2R,12bS)-2'-oxospiro[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2, 
3-a]quinolizine-2,5'-imidazolidine]-1'-yl]ethyl]methanesulfonamide (IUPAC) 
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MK-467 was first introduced as L-659,066 by Clineshcmidt et al. (1988) as a novel, 
peripherally active 2-adrenoceptor antagonist. Structurally, MK-467 is a spirocyclic-
substituted benzofuroquinolizine without an imidazoline-ring structure and has a 
molecular weight of 418.7. In their pioneer study, the researchers showed that 
systemically administered MK-467 did not reverse clonidine-induced mydriasis in 
rats, while it attenuated an increase in diastolic blood pressure by UK-14,304, a 
selective 2-adrenoceptor agonist. The potency of MK-467 in antagonizing the 
increase in withdrawal times of UK-14,304-pretreated mice exposed to a hot-plate 
proved low. The authors also studied the distribution of systemically administered 
radiolabelled MK-467 into the central nervous system of rats and marmosets, finding 
that the brain:plasma ratios for both total radioactivity and the free drug 
concentrations were approximately 1:20. As for 21 receptor selectivity, both in vivo
and in vitro studies demonstrated a substantial preference for the 2-adrenoceptor, 
with ratios ranging from 30–100:1 depending on the study setting (Clineschmidt et 
al., 1988). Later, MK-467 was reported not to affect dexmedetomidine-induced 
sedation in rats (Doze et al., 1989). 
2.7.1 Cardiovascular effects of MK-467 
MK-467 was shown to increase heart rates in concert with a slight decrease in mean 
arterial pressure in conscious rats, an effect that was suggested to be due to 
increased noradrenaline release due to a decrease in vasomotor tone induced via 
peripheral 2-adrenoceptor antagonism (Szemeredi et al., 1989). In healthy human 
volunteers, MK-467 caused a small increase in systolic blood pressure within one 
hour of peroral administration (Warren et al., 1991). Intravenously administered MK-
467 did not alter supine or erect systolic blood pressures in humans, although a 
slight increase in heart rates was observed when compared to placebo (Schafers et 
al., 1992). Moreover, MK-467 did not significantly accentuate or attenuate exercise-
induced increases in heart rate and arterial blood pressure in healthy volunteers 
(Sciberras et al., 1994).  
   In dogs, MK-467 administered as an intravenous infusion dose-dependently 
increased heart rates and cardiac output while reducing systemic vascular resistance 
when measured 30 minutes after drug administration. No significant effects on mean 
arterial pressures were observed (Pagel et al., 1998). Enouri et al. (2008) reported 
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similar findings five minutes after rapid intravenous administration of a single dose of 
MK-467 in dogs. 
2.7.2 Other effects of MK-467 
MK-467 reduced the urine output in normally hydrated rats, but had little effect on 
rats that were void of the antidiuretic hormone (ADH), leading the authors to suggest 
that 2-adrenoceptor agonists inhibit the action of ADH in the collecting tubules 
(Jackson et al., 1992). In healthy human volunteers, no effects on resting blood 
glucose or insulin levels were detected after treatment with MK-467, although an 
increased response in insulin and free fatty acid levels was observed after exercise 
(Schafers et al., 1992; Sciberras et al., 1994). Both of these studies in humans 
confirmed an increase in plasma noradrenaline concentrations after administration of 
MK-467. 
2.7.3 Pharmacokinetics of MK-467 
No published reports on the pharmacokinetics of MK-467 in any species were 
located. In humans, plasma concentrations ranging from 165–890 ng/mL have been 
reported after differing dosing regimens (Schafers et al., 1992; Sciberras et al., 
1994).
2.8 Atipamezole 
Figure 4. Atipamezole. 5-(2-ethyl-1,3-dihydroinden-2-yl)-1H-imidazole (IUPAC) 
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Atipamezole is a specific 2-adrenoceptor antagonist, with an 21 selectivity ratio of 
8500:1. Atipamezole reverses the central and peripheral effects of both 
medetomidine and dexmedetomidine in dogs (Vähä-Vahe, 1990; Vainio, 1990; 
Flacke et al., 1990). Atipamezole contains an imidazoline-ring and has a molecular 
weight of 212.3. There are no published reports on the cardiovascular or central 
function when administered alone in dogs. In healthy human volunteers, increasing 
plasma concentrations of atipamezole induced moderate elevations in diastolic and 
systolic arterial pressures, with negligible effects on overall heart rates (Penttilä et 
al., 2004). 
2.9 The use of antimuscarinic drugs with 2-adrenoceptor agonists 
Antimuscarinics, such as atropine and glycopyrrolate, exhibit their action via 
muscarinic receptors expressed mainly in the sinoatrial, atrioventricular and atrial 
myocardium in the canine heart (Kent et al., 1974). Both drugs act as vagolytics, 
thus enhancing sinoatrial automacity and atrioventricular conduction. They have 
been used to counteract vagally mediated bradycardia, as they increase the heart 
rate and blood pressure (Plunkett and McMichael, 2008). Consequently, they have 
been studied in either the prevention or correction of bradycardia induced by 2-
adrenoceptor agonists in dogs. Short (1991) described an elevated incidence of 
cardiac dysrhythmias when atropine or glycopyrrolate was administered after 
medetomidine in dogs, and reported similar, whilst less severe, outcomes when the 
two antimuscarinics were given pre-emptively. Alibhai et al. (1996) noted prolonged 
hypertension in a similar study setting. Intramuscular administration of increasing 
doses of medetomidine in atropine-preteated (IM) dogs led to severe hypertension, 
irrespective of the dose administered, when compared to medetomidine alone (Ko et 
al., 2001). Furthermore, Alvaides et al. (2008) reported pronounced hypertension 
induced by dexmedetomidine in atropine-premedicated dogs, an effect that was only 
slightly attenuated by acepromazine, an 1-adrenoceptor antagonist tranquilizer. 
   Importantly, Bloor et al. (1992a) had already demonstrated that while pre-treatment 
with glycopyrrolate did prevent the reduction in heart rates induced by 
dexmedetomidine, the cardiac index was only moderately improved and returned to 
baseline levels only after reversal with atipamezole. More recently, Congdon et al. 
(2011) confirmed a similar decrease in cardiac output after both dexmedetomidine 
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(IM) and dexmedetomidine with atropine (IM) in conscious dogs. In this study, 
ventricular arrhythmias (ventricular premature contractions and ventricular bigemini) 
were also observed when dexmedetomidine was given with the antimuscarinic drug. 
2.10 Current knowledge of concomitant use of dexmedetomidine and MK-467 
In a pioneering study, Doze et al. (1989) found that MK-467 was unable to 
antagonize the hypnotic action of dexmedetomidine in rats, while idaxozan, a central 
and peripheral 2-adrenoceptor antagonist, completely abolished its central effects. 
No studies on the effects of MK-467 on medetomidine or dexmedetomidine-induced 
sedation in dogs were located. 
   In a detailed investigation, Pagel et al. (1998) demonstrated that MK-467 was able 
to dose-dependently attenuate the cardiovascular effects of dexmedetomidine in 
dogs. The authors used infusion regimens to administer increasing doses of MK-467 
(0.1, 0.2 and 0.4 mg/kg IV) prior to a 5 μg/kg dose of dexmedetomidine with a 24 h 
wash-out period between treatments. Measurements were made at baseline, 30 
minutes after MK-467 and 5 and 60 minutes after dexmedetomidine. They reported a 
typical early hemodynamic outcome after dexmedetomidine alone, albeit only a 
moderate early decrease in heart rate. In contrast, MK-467 induced a reduction in 
systemic vascular resistance coupled with an increase in the heart rate and cardiac 
output, resulting in stable mean arterial pressures. After MK-467, dexmedetomidine 
was able to reduce heart rates with all but the highest MK-467 dose. Surprisingly, the 
bradycardic effect was less pronounced with dexmedetomidine alone. However, as 
afterload was decreased with higher doses of MK-467, cardiac output was better 
maintained in the presence of the antagonist. The authors postulated that while MK-
467 accentuated the later central sympatholytic effects of dexmedetomidine, as 
described by more pronounced reductions in mean arterial and left ventricular 
systolic pressures, the overall outcome was balanced out by the peripheral post-
synaptic 2-adrenoceptor antagonism. 
   Similarly, premedication with 0.2 mg/kg of MK-467 IV attenuated the 
cardiopulmonary effects of 10 μg/kg of medetomidine in dogs (Enouri et al., 2008). 
Again, medetomidine administration led to a decrease in the heart rate and cardiac 
index, but the effects were significantly less in the presence of the antagonist. MK-
467 had no effect on respiratory rates or arterial blood gases when compared to 
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saline premedication, although the antagonist attenuated the increase in 
medetomidine-induced tissue oxygen extraction ratio, proving the significance of the 
reduction in tissue oxygen delivery in the absence of the antagonist. Furthermore, 
combining glycopyrrolate (5 μg/kg) with MK-467 showed no further hemodynamic 
improvement or a significant increase in oxygen delivery. 
   Earlier, Hayashi et al. (1991) noted that while MK-467 did not affect the 
antiarrhythmic effect of dexmedetomidine when halothane-anesthetized dogs were 
administered adrenaline, it reduced blood pressures and increased heart rates 
compared to dexmedetomidine alone. This effect was not seen when MK-467 was 
administered cerebroventricularly in a similar study setting (Kamibayashi et al., 
1995b).
   In horses and sheep pretreated with methoxamine (an 1-adrenoceptor agonist), 
MK-467 attenuated medetomidine-induced hypertension and bradycardia (Bryant et 
al., 1998). Furthermore, simultaneous administration of 250 μg/kg of MK-467 
abolished all cardiovascular effects of 5 μg/kg of dexmedetomidine in conscious 
sheep (Raekallio et al., 2010). 
   Recently, Restitutti et al. (2012) demonstrated that MK-467 blunted both the 
decrease in plasma insulin and the increase in glucose concentrations induced by 
dexmedetomidine in dogs. These findings are consistent with previous reports on the 
effects of MK-467 on clonidine-induced changes in plasma insulin and glucose levels 
in humans (Warren et al., 1991). 
   MK-467 has also been shown to prevent the analgesic action of dexmedetomidine 
in rats with peripherally induced neuropathy, leading the authors to suggest that 
peripheral 2-adrenoceptors may play a role in the modulation of neuropathic pain 
outside the central nervous system (Poree et al., 1998). Elsewhere, MK-467 had no 
effect on the antinociceptive effects of dexmedetomidine in acute visceral pain 
induced by colorectal distension (Ulger et al., 2009). 
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3. Aims of the study 
1) To investigate the effects of various doses of MK-467 on the cardiopulmonary 
action of dexmedetomidine, with special reference to simultaneous 
administration. 
2) To characterize the effects of MK-467 and dexmedetomidine on their plasma 
concentrations and describe their clinical consequences. 
3) To define any short-term clinical or cardiopulmonary adverse effects of MK-
467 when administered alone. 
4) To evaluate the clinical quality of dexmedetomidine-induced sedation in the 
presence of MK-467 and its reversal with atipamezole 
Material and methods 
26
4. Material and methods 
4.1 Animals and instrumentation 
In Study I, six healthy neutered laboratory beagles, three males and three females, 
were used. They were aged between 9 and 11 years and no invasive monitoring 
techniques were applied. 
   For the rest of the studies (II–IV), eight healthy laboratory beagles, six males and 
two females, were used. The dogs were neutered six months prior to the first 
experiments and adapted to both handling and the research environment. These 
dogs were aged 15 (2.3) months (mean (SD)) during the experiments. 
   All dogs were routinely vaccinated and dewormed, and they were housed in 
groups with daily access to outdoor exercise and fed a commercial diet. The health 
status of the dogs was assessed by thorough clinical examinations, complete blood 
counts and routine serum chemistry, repeated periodically and when thought 
necessary.
   In study I, a venous catheter was placed into the cephalic vein of the dogs and no 
other invasive instrumentation was applied. For studies II–IV, the arterial and central 
venous catheterizations were performed under sevoflurane anesthesia and after 
extubation, the dogs were allowed to recover for a minimum of one hour prior to 
baseline measurements. All studies were approved by the National Animal 
Experimentation Board. 
4.2 Drugs and dosages 
A summary of the performed studies is presented in Table 1. Dexmedetomidine 
(Dexdomitor, Orion Pharma, Turku, Finland), atipamezole (Antisedan, Orion 
Pharma) and MK-467 (Merck, Sharpe&Dohme, PA, USA) were used in the studies. 
Commercial preparations of dexmedetomidine and atipamezole were used and 
diluted where appropriate, whereas MK-467 was supplied as a powder and 
reconstituted with saline in a sterile vial to form a clear, homogeneous injectable 
solution (1 mg/mL) prior to each treatment. All IV drug treatments were drawn into a 
single syringe and further diluted with saline to an equal final volume of 10 mL. In 
study I, atipamezole was given undiluted. 
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   In study I, 5 μg/kg of dexmedetomidine with or without 250 μg/kg of MK-467 was 
administered IV to each dog on two separate occasions with a minimum seven-day 
wash-out period between treatments. Atipamezole (50 μg/kg) was administered IM 
40 minutes after both treatments. 
Table 1. Summary of study protocols. 
Study 
Number of 
animals 
Treatments 
(µg/kg, IV) 
Primary outcome Secondary outcome(s) 
I 6
a. D 5
b. D 5 + MK 250 
ATI 50 (IM) 
Clinical sedation 
Pulse rate, atipamezole 
reversal
II 8
a. D 10
b. D 10 + MK 250 
c. D 10 + MK 500 
d. D 10 + MK 750 
e. MK 250 
Cardiorespiratory 
parameters
III 8 Clinical sedation
IV 8 (5) Plasma concentrations 
D = dexmedetomidine, MK = MK-467, ATI = atipamezole 
   In studies II–IV, 10 μg/kg of IV dexmedetomidine was given alone or in 
combination with 250, 500 or 750 μg/kg of MK-467. Additionally MK-467 (250 μg/kg) 
was also given alone. Each dog was hence studied five times and a minimum wash-
out period of 14 days was allowed between treatments. Intravenous treatments were 
administered over a 30–second period in all studies. 
4.3 Cardiorespiratory monitoring 
In study I, pulse rates were assessed by manual femoral pulse wave assessments 
during 30 seconds. In an effort to minimize monitoring-induced alterations in the level 
of sedation, no other cardiovascular methods were applied after drug administration. 
On a separate occasion, a light (150 g), portable Holter-monitoring device designed 
by Hyvärinen et al. (2006) was also used in order to obtain minimum resting heart 
rates for comparison with treatment-induced pulse rates. The monitor was integrated 
in a textile vest that all dogs became accustomed to wearing prior to the recordings. 
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   In study II, a modular multiparameter monitor (S/5 Compact Critical Care Monitor, 
Datex-Ohmeda, Hatfield, UK) was used to record a continuous lead II 
electrocardiogram as well as invasive arterial and central venous pressures. Arterial 
catheters were placed into the metatarsal artery and the double lumen central 
venous catheters were introduced via the jugular vein. Both invasive pressure 
transducers were calibrated prior to baseline measurements (X-Caliber®, Datex-
Ohmeda). 
   Samples for arterial blood gas analysis were taken via the metatarsal arterial 
catheter into pre-heparinized syringes, stored in iced water and analyzed within 90 
minutes. The arterial hemoglobin content, pH, PaO2, PaCO2, bicarbonate (HCO3-),
electrolyte and lactate concentrations were recorded using a Radiometer ABL-800 
Flex (Radiometer, Copenhagen, Denmark) analyzer. As the dogs were breathing 
room air during study II, P(A-a)O2 was also provided by the analyzer. Respiratory 
rates were calculated by observing chest wall movements.   
   Cardiac output measurements were performed with the lithium dilution method 
(LidCO™Plus Hemodynamic Monitor, LidCO Ltd, Cambridge, UK), as previously 
described in dogs (Mason et al., 2001). The LidCO computer requires blood 
hemoglobin and sodium concentrations to produce accurate CO values, and 
standard concentrations of 10 g/dL and 140 mmol/L were used for hemoglobin and 
sodium, respectively. As these values were simultaneously acquired with the blood 
gas analyzer but analyzed with a delay, LidCo Ltd provided the investigators with a 
formula that allowed the correction of CO values, integrating the actual 
concentrations for both required parameters. The PulseCo feature of the monitor, 
which yields a continuous CO estimate derived from the arterial pulse waveform, 
was not used during the experiments. 
   The following formulae were used to calculate the derived parameters in study II: 
• Cardiac index (mL/kg/min) = cardiac output / body weight (Boyd et al., 1991) 
• Systemic vascular resistance (dynes x s x cm-5) = 80 x (MAP-CVP) / CO (Boyd et 
al., 1991); 
• Arterial hemoglobin saturation (%) = [37 900/(PaO23 + 205 x PaO2) + 1] -1 (Reeves 
et al., 1982); 
• Arterial blood oxygen content (mL/mL) = [(1.39 x Hb x SaO2) + (0.0031 x PaO2)] x 
0.01 (Boyd et al., 1991); 
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• Oxygen delivery (mL/kg/min) = Cardiac index x Arterial blood oxygen content (Boyd 
et al., 1991); 
• Alveolar-to-arterial oxygen partial pressure difference = {0.21 x (pressureambient – 
6.275) – pCO2 x [RQ-1 – 0.21 x (RQ-1 – 1)] } – PaO2 , where RQ (respiratory quotient) 
is 0.86 by default (Radiometer ABL800 Flex Reference Manual). 
4.4 Plasma concentrations of dexmedetomidine 
Blood samples for analysis of plasma dexmedetomidine concentrations were taken 
in study IV. Samples were obtained via a designated port of the central venous 
catheter, centrifuged and stored at -20 °C until analyzed with liquid chromatography-
mass spectrometry as previously described (Snapir et al., 2006). Standard software 
(WinNonlin Professional software package, version 5.2, PharSight Corporation, 
Mountain View, CA, USA) was used to calculate common pharmacokinetic 
parameters using non-compartmental methods. Half-lives for the distribution and 
elimination phases were calculated with a two-compartment IV bolus model with no 
lag time and first-order elimination. 
4.5 Plasma concentrations of MK-467 
MK-467 concentrations in plasma from five dogs in study IV were analyzed with 
liquid chromatography–mass spectrometry after liquid-liquid extraction and with 
yohimbine as an internal standard. After reversed-phase separation (Gemini 5 C18
110A, 150 x 2.0 mm, Phenomenex), quantitative detection was performed in a multi-
reaction monitoring mode (MRM) with a triple quadrupole mass spectrometer (AB 
Sciex API 4000). For MK-467 and yohimbine, the precursor ions were scanned at 
m/z of 419.0 and 355.0, respectively. The fragment ions monitored for MK-467 had 
m/z values of 127.0 and 200.0 and those for yohimbine were 212.0 and 144.0. The 
chromatograms were analyzed and processed using AB Sciex software (Analyst 
4.1). Pharmacokinetic parameters were calculated with non-compartmental methods 
as described above for dexmedetomidine. 
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4.6 Clinical assessment of sedation 
Sedation was subjectively assessed in studies I and III by an investigator blinded to 
the treatments. In study I, a composite sedation score designed by Kuusela et al. 
(2000) was applied. The same scoring system was used in study III with minor 
modifications (i.e. omitting the significance of spontaneous recumbency, as the dogs 
were gently held in a lateral position when necessary, regardless of the treatment). 
In study I, sedation scoring was continued for 20 minutes after atipamezole 
administration. In study III, sedation assessments were made up until 90 minutes 
after drug administration, with the exception of MK-467 alone, where the experiment 
was discontinued after 60 minutes. The area under the time-sedation curve was 
calculated by a trapezoidal method. 
4.7 Methods for analgesia during the experiments 
Due to repeated catheterizations, local infiltration of 5 mg of lidocaine (Lidocain® 20 
mg/mL, Orion Pharma) was applied for each catheter insertion site, and 0.2 mg/kg of 
meloxicam (Metacam 5 mg/mL, Boehringer Ingelheim Vetmedica GmbH, Ingelheim, 
Germany) was administered intravenously at the end of each experiment in studies 
II–IV.
4.8 Study designs 
Dexmedetomidine was chosen as the positive control in all studies, and no negative 
controls were used. In study I, the treatments were randomly allocated in a cross-
over design and the investigator assessing sedation was blinded to the treatment. In 
studies II–IV, where five different treatments were investigated, a similar random 
allocation was applied, and the investigator monitoring sedation in study III was 
blinded to the treatment. 
4.9 Statistical analysis 
Repeated-measures analysis of variance was applied for numerical variables 
throughout the studies, followed by a post-hoc correction between treatments and 
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against baseline measurements where applicable. The Bonferroni post hoc
correction was used for all comparisons except for the pulse/heart rates in study I, 
where the Dunnett’s correction was used (minimum resting heart rate as the control).
Shapiro-Wilk’s test was used to evaluate whether the data followed a normal 
distribution. Bioequivalence was assessed as recommended by the European 
Medicines Agency (2001) in studies I and III. Data are expressed as the mean (CI95) 
and/or mean (SD). Values of p < 0.05 were considered significant. Data for studies 
II–IV were collected during the same series. 
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5. Results 
5.1 Cardiovascular effects 
5.1.1 Cardiovascular effects of dexmedetomidine (I, II) 
Intravenous dexmedetomidine administration (10 μg/kg) in study II was followed by a 
rapid increase in systolic, mean, diastolic and central venous blood pressures, 
accompanied by a marked reduction in heart rate and cardiac index (Table 2). 
Consequently, systemic vascular resistance considerably increased and oxygen 
delivery was significantly reduced. All of these effects were most pronounced five 
minutes after dexmedetomidine administration. However, despite the following 
gradual reductions in systemic blood pressures after the initial hypertension, heart 
rates, cardiac index and oxygen delivery remained significantly below baseline levels 
throughout the 90-minute period. Moreover, systemic vascular resistance remained 
elevated when compared to the baseline. In accordance, 5 μg/kg of 
dexmedetomidine significantly reduced pulse rates from 5 to 40 minutes in study I. 
Atipamezole increased pulse rates within 10 minutes of IM administration, although 
baseline levels were not reached within the follow-up period. 
   Accentuated sinus bradyarrhythmia was the most common ECG abnormality 
observed after dexmedetomidine administration in study II. During the early 
observational period, and especially during the first five minutes, second-degree 
atrio-ventricular blocks were occasionally seen in all but one dog. First-degree atrio-
ventricular blocks and prolonged sinus pauses were detected in all dogs. In two 
dogs, a single ventricular escape beat was detected between 10 and 20 minutes 
after administering dexmedetomidine, and in one dog, a total of four individual 
ventricular escape beats were seen within 10 minutes of drug administration. 
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5.1.2 Cardiovascular effects of MK-467 (II) 
In study II, 250 μg/kg of MK-467 IV was followed by a rapid increase in the heart 
rate, cardiac index and oxygen delivery with no apparent changes in arterial or 
central venous pressures and a moderate but statistically significant decrease in 
systemic vascular resistance (Table 2). The median heart rate five minutes after MK-
467 was 143/min, and the highest individual heart rate recorded was 208/min. All 
parameters started to return towards the baseline ten minutes after drug 
administration, and while both the cardiac index and oxygen delivery remained 
slightly elevated accompanied by the decrease in systemic vascular resistance, no 
statistically significant differences were found after 60 minutes when compared to the 
baseline. Besides the transient sinus tachycardia, no further ECG abnormalities were 
detected after MK-467 administration. 
5.1.3 Cardiovascular effects of dexmedetomidine combined with MK-467 (I, II) 
In study I, simultaneous administration of 250 μg/kg of MK-467 with 5 μg/kg of 
dexmedetomidine attenuated the bradycardia. Although pulse rates did decrease 
significantly, they remained above 60 bpm and were assessed as bioequivalent with 
the minimum resting heart rates acquired from the overnight Holter monitoring. 
Atipamezole increased pulse rates within 10 minutes, but similarly to 
dexmedetomidine alone, baseline levels were not reached. 
   In study II, MK-467 had a dose-dependent effect on the hemodynamic alterations 
induced by dexmedetomidine (Table 2). With the lowest dose (250 μg/kg), some 
early effects attributable to dexmedetomidine (bradycardia, increased central venous 
pressure, decreased cardiac index and oxygen delivery) were still evident. While no 
early hypertension was observed, mean arterial blood pressures decreased 
significantly after 20 minutes and remained below the baseline until 90 minutes. The 
lowest mean arterial pressures were recorded between 45 and 60 minutes after drug 
administration, with one dog having a single value below 60 mmHg (59 mmHg). 
Systemic vascular resistance, the cardiac index and oxygen delivery did not differ 
significantly from baseline values after five minutes. First-degree atrio-ventricular 
blocks were detected in all and second degree atrio-ventricular blocks were also 
seen in four dogs during the first five minutes. 
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   With the 500 μg/kg dose, no statistically significant cardiovascular changes were 
seen when compared to the baseline at five minutes. Mean arterial pressures were 
significantly reduced from 10 to 90 minutes and heart rates were below baseline 
values from 30 minutes. Three MAP measurements were below 60 mmHg, with the 
lowest value being 58 mmHg. These were all from the same dog between 20 and 45 
minutes. On the other hand, the cardiac index and oxygen delivery were maintained 
at baseline levels for the duration of the observational period. No ECG abnormalities 
were seen. 
   With the highest dose of 750 μg/kg, no significant differences in heart rates from 
the baseline were seen during the observational period. However, mean arterial 
pressures were reduced from 5 until 75 minutes, with one dog having values 
between 55–59 mmHg between 10 to 45 minutes (this was the same dog that had 
the low values with the previous doses). No significant difference in either cardiac 
index or oxygen delivery was observed compared to the baseline, while systemic 
vascular resistance was reduced between 20 and 60 minutes. No ECG alterations 
were observed. 
5.2 Respiratory effects 
5.2.1 Respiratory effects of dexmedetomidine (II) 
Dexmedetomidine reduced respiration rates in study II (Table 3) when given alone 
along with a moderate but statistically significant early decrease in PaO2 with the 
dogs breathing room air (Figure 5). No significant differences in PaCO2 were 
observed when compared to the baseline (range 27.7–41.1 mmHg). Consequently, 
an elevation in alveolar-to-arterial oxygen partial pressure differences was observed. 
However, arterial oxygen saturations remained above 90% at all times, except for 
two dogs that had a PaO2 value below 60 mmHg between 10 and 30 minutes. PaO2
and P(A-a)O2 returned to baseline levels from 45 minutes. Inconsequential, but 
statistically significant decreases in arterial pH and HCO3- concentrations were also  
observed. Arterial blood lactate levels rose compared to the baseline, although no 
single value reached >2 mmol/l. 
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Figure 5. Arterial partial pressures of carbon dioxide (PaCO2) and oxygen (PaO2).
Error bars indicate 95% confidence intervals
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5.2.2 Respiratory effects of MK-467 (II) 
MK-467 had no significant effect on the respiration rate when administered alone 
(Table 3). Furthermore, no changes in PaO2 or PaCO2 were seen (Figure 5). Arterial 
pH and lactate concentrations showed a decreasing trend, reaching statistical 
significance at some time points, as did the HCO3- concentrations. 
5.2.3 Respiratory effects of dexmedetomidine combined with MK-467 (II) 
Respiratory rates tended to be somewhat higher than with dexmedetomidine alone 
(Table 3). MK-467 did not improve PaO2 values at any dose level, but early arterial 
oxygen tensions were instead slightly lower when compared to dexmedetomidine 
alone (Figure 5). The differences did not reach statistical significance at any time 
point. PaCO2 was significantly higher with the two higher dose levels of MK-467 at 
some time points when compared to dexmedetomidine. However, no PaCO2 values 
above 45 mmHg were detected with any treatment including the antagonist. 
Changes in P(A-a)O2 were similar between all treatments that included 
dexmedetomidine. Small albeit statistically significant reductions in arterial pH were 
seen with every MK-467 dose, although the lactate levels decreased with 500 and 
750 μg/kg when compared to the baseline and were significantly lower than with 
dexmedetomidine alone (Table 3). 
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5.3 Plasma drug concentrations 
5.3.1 Plasma concentrations of dexmedetomidine (IV) 
In study IV, MK-467 had a marked influence on the plasma concentrations of 10 
μg/kg of IV dexmedetomidine (Table 4). Regardless of the dose of MK-467, plasma 
concentrations were significantly reduced when compared to dexmedetomidine 
alone. Statistical significance was reached from 10 to 60 minutes with 250 μg/kg of 
MK-467, from 5 to 60 minutes with 500 μg/kg of MK-467 and from 5 to 90 minutes 
with 750 μg/kg of MK-467. Consequently, the AUC0–90 with dexmedetomidine alone 
was significantly larger when compared to treatments including the antagonist. 
Similarly, the calculated volumes of distribution and clearance were higher with MK-
467. Neither the distribution nor terminal half-life estimates differed significantly 
between treatments. On visual inspection of the data, however, the distribution of 
dexmedetomidine from the central compartment gave an impression of being more 
rapid when the drug was co-administered with MK-467. Modeling after 
dexmedetomidine alone provided rather poor fits with the employed simple two-
compartment model. This resulted in poor accuracy and wide scatter of the 
distribution half-life estimates. 
5.3.2 Plasma concentrations of MK-467 (IV) 
Plasma concentrations were successfully determined in five dogs. The volume of 
distribution was estimated at 0.41 (0.13) L/kg. Simultaneously administered 
dexmedetomidine had no significant effect on the AUC0-60 of MK-467, while a non-
linear dose exposure was evident between the two higher doses of MK-467. Plasma 
concentrations are summarized in Table 4. 
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Table 4. Concentrations of dexmedetomidine and MK-467 in plasma (mean (CI95%)). 
Time
(min) 
1 3 5 10 20 30 45 60 90
Treatment Concentrations of dexmedetomidine in plasma in eight dogs (ng/mL) 
D 15.3
(4.2)
11.6
(2)
11.5
(2.1)
9.4
(1.9)
6.4
(1.2)
4.7
(0.8)
3.5
(0.6)
2.7
(0.4)
1.5
(0.3)
DM25 12.6 
(1.8)
9.4 
(0.7)
7.3 
(0.7)
4.4 
(0.7)
2.8
(0.4)
2
(0.4)
1.5 
(0.2)
1.1 
(0.2)
0.8 
(0.2)
DM50 12
(1.8)
8.2 
(1)
6
(0.7)
3.6 
(0.5)
2.3 
(0.4)
1.8 
(0.3)
1.2 
(0.2)
1
(0.2)
0.7 
(0.2)
DM75 10.5 
(2.1)
8.3 
(2.8)
5.8
(1)
3.4 
(0.6)
2.4 
(0.4)
1.8 
(0.3)
1.5 
(0.3)
1.1 
(0.2)
0.7 
(0.2)
Concentrations of MK-467 in plasma in five dogs (µg/mL) 
M25 1.44 
(0.26) 
0.93 
(0.27) 
0.7 
(0.3)
0.56 
(0.23) 
0.45 
(0.19) 
0.36 
(0.16) 
0.29 
(0.12) 
0.22 
(0.11) 
NM
DM25 1.81 
(0.47) 
1.0 
(0.31) 
0.69 
(0.24) 
0.55 
(0.14) 
0.37 
(0.11) 
0.31 
(0.1)
0.28 
(0.08) 
0.23 
(0.1)
0.16 
(0.06) 
DM50 2.89 
(0.72) 
1.67 
(0.66) 
1.46 
(0.59) 
1.25 
(0.41) 
0.88 
(0.36) 
0.7 
(0.4)
0.63 
(0.34) 
0.45 
(0.25) 
0.41 
(0.26) 
DM75 2.74 
(0.55) 
1.62 
(0.39) 
1.55 
(0.75) 
1.25 
(0.37) 
0.91 
(0.34) 
0.87 
(0.45) 
0.65 
(0.31) 
0.57 
(0.27) 
0.4 
(0.27) 
NM = not measured 
5.4 Clinical sedation (I, III) 
In study I, MK-467 did not significantly influence the composite sedation scores 
during individual time points; nor did it affect the area under the time–sedation curve. 
Time to lateral recumbence after drug administration was similar with both 
treatments (mean (CI95)): 81 (41) seconds with D 5 and 88 (44) seconds with D 5 + 
MK 250). The degree of sedation decreased rapidly after atipamezole with both  
treatments. Four dogs scored a CSS > 0 (range 1–5) with D 5, and all dogs had a 
CSS score of zero with D 5 + MK 250 at the end of the observational period.  
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In study III, MK-467 did not have a sedative or a stimulating effect when 
administered alone. After all treatments that included dexmedetomidine, each dog 
became moderately or deeply sedated. The sedation scores were lower when 
dexmedetomidine was combined with MK-467, reaching statistical significance with 
250 and 500 μg/kg. However, bioequivalence between dexmedetomidine and 
combinations with all doses of MK-467 was reached for areas under time–sedation 
curve calculated for the composite sedation scores. Confidence intervals for the 
areas under the time-sedation curves are presented in Table 5. 
Table 5. Confidence intervals of the calculated areas under time-sedation (studies I 
and III) and time-concentration (study IV) curves for sedation and plasma 
concentrations of dexmedetomidine. Dexmedetomidine/MK-467 combinations are 
compared to dexmedetomidine alone. 
Study DOP (min) Treatment AUCCSS AUCRATIO 
AUCRATIO 
(CI95)
AUCRATIO
(CI97.5) 
I
(n=6) 
40
D5 13.6
DM25 12.7 0.93 0.78 – 1.08 0.76 – 1.11
AUCREC
20
D5 7.0
DM25 5.5 0.79 0.42-1.16 0.37-1.21
AUCCSS
III (n=8) 90
D10 11.1
DM25 9.3 0.84 0.76 – 0.92 0.75 – 0.93
DM50 9.7 0.87 0.75 – 1.0 0.73 – 1.01
DM75 8.8 0.79 0.71 – 0.87 0.71 – 0.88
AUCDEX
IV (n=8) 90
D10 422
DM25 215 0.51 0.42 – 0.6 0.41 – 0.61
DM50 188 0.46 0.38 – 0.54 0.37 – 0.56
DM75 189 0.46 0.38 – 0.54 0.37 – 0.56
DOP = duration of observation/sampling period 
AUCCSS = area under time-sedation curve / DOP 
AUCREC = area under time-sedation curve after 50 μg/kg of atipamezole (IM) / DOP 
AUCDEX = area under time-concentration curve of dexmedetomidine 
AUCRATIO = AUCCOMBINATION / AUCDEXMEDETOMIDINE 
CI95 and CI97.5 = 95% and 97.5% confidence intervals for AUCRATIO 
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6. Discussion 
6.1 Methodological considerations 
The dogs in study I were in good general health, although they already aged from 9 
to 11 years during the experiment. Thus, both the cardiovascular and sedation 
outcomes from this study are not necessarily comparable with studies II–IV, in which 
eight young beagles were used. The elimination rate of dexmedetomidine has been 
suggested to be higher in juvenile beagles (3-4 months) than in adults (> 2 years) 
(EMA, 2002). In aging humans, a reduced vasoconstrictive effect in leg musculature 
has been demonstrated with dexmedetomidine (Smith et al., 2007). No studies on 
the effects of ageing on the hypnotic potency of dexmedetomidine were located, 
although Fragen and Fidgerald (1999) reported a lower sevoflurane MAC-sparing 
effect of dexmedetomidine in older humans when compared to the previously 
documented isoflurane MAC-sparing percentage (Aantaa et al., 1997). The younger 
beagles used in studies II–IV obviously had less time to adapt to the experiments, 
and while every effort was made to minimize the effect of the methods on the 
outcomes, baseline cardiopulmonary parameters might well have been influenced by 
the mere activity of the animals. In fact, in study II, baseline mean arterial pressures 
were higher than expected for resting dogs. 
   In study I, the pulse rates after treatments were compared with the resting heart 
rates obtained by Holter-monitoring. As these two parameters are not necessarily 
analogous, ECG monitoring during the treatment period would have allowed more 
appropriate comparisons to be made. However, by definition, the pulse rate cannot 
be higher than the heart rate. Thus, the heart rate would at worst have been 
underestimated during sedation after either treatment. 
   In studies I and III, bioequivalence was demonstrated according to the veterinary 
guidelines provided by the European Medicines Agency (EMA 2001). As these 
requirements were primarily designed to form the basis for approval of generic 
applications and thus mainly focused on the pharmacokinetic behavior of two 
products that are presumed identical, the use of these guidelines to accept or reject 
bioequivalence between two or more pharmacodynamic outcomes might not have 
been an optimal test. Furthermore, the CI90% acceptance interval (0.8–1.25) 
suggested by the EMA was not necessarily applicable to the hypothesis of the 
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present studies (bioequivalence in sedation). For example, the World Health 
Organization recommends customized acceptance intervals that should be justified 
both statistically and clinically in order to find any relevant difference with reasonable 
sensitivity (WHO, 2009). The WHO also recommends the use of CI95% instead of 
CI90% for equivalence studies. However, specific acceptance intervals would have 
required a consensus on a clinically relevant difference, and as the composite 
sedation score used in the studies has not been appropriately validated, EMA 
guidelines provided established limits for assessing the potential similarity between 
treatments. In any case, clinical bioequivalence between treatments should be 
accepted with caution. 
   Power analyses were performed for primary and selected secondary outcomes 
prior to all studies. Eight dogs were chosen for studies II–IV, as compared to six in 
study I, in an effort to detect smaller significant differences, especially during the 
later stages of both the cardiopulmonary and sedation monitoring. As 95% 
confidence intervals were calculated for most parameters, it became clear that some 
differences that did not reach statistical significance might still remain clinically 
important. This was especially observed when arterial partial pressures of oxygen 
were compared between treatments. The use of harsh post hoc corrections, such as 
the Bonferroni, probably highlighted this effect with parameters that had wide 
standard deviations. On the other hand, false positive results were less likely, which 
is commonly accepted as a more appropriate approach. 
   The main investigator was not blinded to the treatments, but as the 
cardiopulmonary parameters were numerical and, for the most part, recorded 
automatically by the use of collecting software, it was deemed as an acceptable flaw 
and thought not to influence the outcomes. A second investigator assessing 
subjective central effects was kept unaware of the treatment given and 
cardiopulmonary monitoring parameters, which fulfilled the criteria of blinding.  
However, as the administration of MK-467 alone in study III resulted in no apparent 
sedation, blinding was not possible. 
   Placebo treatments were not used in any study. Dexmedetomidine acted as a 
positive control in all studies, and as its cardiovascular and central effects were well 
known before-hand to be supraphysiological, the lack of a negative control was 
thought unnecessary, especially as comparisons with the baseline were also carried 
out. However, we cannot consequently rule out any additive or inhibitory effect 
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generated either from the study subjects or the settings on any parameter 
investigated. 
   In studies II–IV, only six dogs were investigated when MK-467 was administered 
alone. This decision was made during the experiments, as it became clear that both 
the central and cardiovascular outcomes were markedly different from all treatments 
including dexmedetomidine. While the resulting difference in group size induced 
some difficulties in treatment comparisons, randomization was not affected. 
   A considerable methodological flaw in study IV was the short duration of sampling 
for plasma drug concentrations. The authors had previous experience in 
pharmacokinetic studies with dexmedetomidine in dogs suggesting that more than 
120 minutes should be allowed for proper elimination of the parent compound 
(Kuusela et al., 2000). That said, the differences in plasma concentrations between 
treatments were large enough to reliably show the effects of MK-467 during the 
clinically most important first hour after drug administration. Within the same study, 
plasma concentrations of MK-467 were successfully analyzed in only five dogs, 
which yielded large deviations. Furthermore, no efforts were made to study the 
possible chemical interaction between dexmedetomidine and MK-467 when mixed 
together in a single syringe prior to administration. Thus, while no macroscopic 
changes such as precipitates or color changes were observed, both the stability and 
integrity of the mixture should be confirmed by vigorous quality assessments to rule 
out any potential chemical incompatibility. However, the pharmacodynamic dose-
response of the treatments in the present study was logical and repeatable. 
   As the results for studies II–IV were yielded from the same series, different 
methods might have affected one another. For example, sedation assessments 
provided a stimulus that may well have influenced the hemodynamic parameters. 
Similarly, the mechanical noise from the infusion pump collecting waste arterial blood 
via the lithium sensor during cardiac output measurements could have affected the 
degree of sedation. Moreover, noise from the surroundings was impossible to 
standardize during the experiments. In effort to minimize these deviations, sedation 
scoring was carried out immediately prior to the cardiac output measurements. 
Furthermore, the conditions did not differ between treatments, and background noise 
was minimized with appropriate announcements to staff working adjacent to the 
research room. 
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   Instrumentation for studies II–IV was carried out under sevoflurane anesthesia. 
After mask induction of anesthesia, the percentage of sevoflurane (in oxygen) varied 
between 2–3.5% during arterial and central venous catheter placement, which 
usually took less than one hour from induction to extubation. Arterial blood pressures 
were indirectly measured by Doppler and a capnograph was used. No relevant hypo- 
or hypertension or hypo-/hypercapnia was detected during the instrumentation 
period. Although the instrumentations were uneventful, it is not possible to exclude 
any effect on the results of the studies, even if a minimum of 60 minutes was allowed 
for recovery between extubation and baseline recordings. Recoveries after 
sevoflurane anesthesia have been reported to be smooth and rapid in dogs 
(Johnson et al., 1998), and although major signaling pathways in the canine CNS are 
affected, the duration of effect appears short and linearly dose-dependent (Stucke et 
al., 2005a and b). Subjectively, all dogs were adequately recovered and showed no 
apparent deviations in their behavior prior to baseline measurements. 
6.2. Cardiovascular effects 
MK-467 dose-dependently attenuated or prevented all the relevant hemodynamic 
alterations induced by dexmedetomidine in this study. This effect was mediated via 
peripheral antagonism of 2-adrenoceptors and proved to be consistent and 
repeatable throughout the study with simultaneous intravenous administration. The 
cardiovascular indices, such as arterial blood pressure, systemic vascular resistance 
and heart rate, clearly indicated that the reduction in early afterload by the antagonist 
was the main single factor that allowed for preserved cardiac function when 
compared to dexmedetomidine alone. Most importantly, the cardiac index and 
oxygen delivery were maintained throughout the observational period in study II with 
dexmedetomidine/MK-467 combinations, and the early cardiovascular disturbances, 
including the incidence of arrhythmias, were either significantly reduced or 
completely abolished by increasing doses of the antagonist. These findings are in 
accordance with other studies on dogs performed with the antagonist and either 
dexmedetomidine or medetomidine, even though the drug administration protocols 
were markedly different (Pagel et al., 1998; Enouri et al., 2008).  
   It is notable that comparisons with studies using racemic medetomidine need to be 
approached with some caution, as levomedetomidine has been demonstrated to 
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have potential agonistic activity at the 1-adrenoceptors and some antagonism at the 
2-adrenoceptors (Schwinn et al., 1991; Kuusela et al., 2000 and 2001a). 
Furthermore, as the 21 specificity of MK-467 is reported to be significantly lower 
than for either agonist drug, some antagonism at the peripheral 1-adrenoceptors 
might have been attributed to its vasodilatatory action (Clineschmidt et al., 1988; 
Virtanen et al., 1988; Vargas and Gorman, 1995). However, acepromazine, an 1-
adrenoceptor antagonist tranquilizer, had only a small attenuating effect on 
dexmedetomidine-induced hypertension in dogs (Alvaides et al., 2008). 
Nevertheless, the marked improvements in the cardiac index and oxygen delivery by 
MK-467 seem to be applicable for both medetomidine (Enouri et al., 2008) and the 
dextroisomer in dogs. 
   After the initial dose-dependent attenuation of the dexmedetomidine-induced 
alterations in hemodynamic performance by MK-467, a trend towards reductions in 
both HR and MAP was observed with each combination treatment. This 
phenomenon would easily be explained by central agonism of 2A-adrenoceptors by 
dexmedetomidine, leading to central sympatholysis and decreases in vasomotor 
tone, as previously shown in knock-out mice (Macmillan et al., 1996; Link et al., 
1996) and in dogs (Pagel et al., 1998). While no severe hypotension was observed 
in the present study, the centrally mediated hypotension might readily be highlighted 
with more multimodal techniques involving cardiopulmonary depression by, for 
instance, induction drugs or inhalant anesthetics (Kuusela et al., 2001b and 2003; 
Bennett et al., 2011). Consequently, although the 50:1 dose ratio in study II provided 
the most stable hemodynamic performance, it might not be optimal when further 
combined with other sedatives, analgesics or general anesthetics. Thus, multimodal 
approaches need to be evaluated separately in order to determine a safe and 
efficacious dose range and ratio. 
   In study I, in which a lower dose of dexmedetomidine was used, MK-467 at a 50:1 
dose ratio was not able to completely reverse the reduction in pulse rates, although 
the pulse rates during dexmedetomidine/MK-467 sedation were bioequivalent with 
the resting heart rates obtained via Holter monitoring. This could reflect differences 
in the study population and experimental setting when compared to study II, in which 
the same dose ratio, although higher absolute doses were administered. The dogs 
used in study I were older and more accustomed to handling, and as the methods 
were kept to an absolute minimum and the experiment was conducted within the 
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kennel they were housed in, physiological stress responses and agitation probably 
had little to no effect on the dose responses. As with all sedatives, a quiet and calm 
environment is necessary to achieve maximal dose effects (Kramer et al., 1996). 
Thus, general sympatholysis after dexmedetomidine might have been more 
accentuated than in study II, allowing for a more profound centrally mediated 
bradycardia. Unfortunately, as factors such as blood pressure, cardiac output and 
catecholamine concentrations were not measured during study I, alternate 
explanations such as different absolute dose effects when lower doses of 
dexmedetomidine are used or the effects of aging cannot be ruled out. It would be 
very unlikely that a lower dose of dexmedetomidine would have induced more 
severe cardiovascular effects (Pypendop et al., 1998; Kuusela et al., 2000), unless 
the absolute dose of MK-467 was insufficient to significantly antagonize the 
peripheral 2-adrenoceptors. Overall, MK-467 acted predictably in its effects on the 
cardiovascular outcome during the studies, which facilitates the design of future 
experiments and the potential transfer to use in clinical patients. 
   When administered alone, MK-467 induced a marked increase in heart rates 
coupled with a moderately decreased systemic vascular resistance. As -
adrenoceptors should have a minimal direct chronotropic effect on the myocardium, 
the tachycardia was probably mediated via a physiological, reactive compensatory 
mechanism in response to the systemic vasodilation by the antagonist drug, as 
previously demonstrated in rats (Szemeredi et al., 1989). While detailed interspecies 
comparisons of the cardiovascular dose response have not been conducted to our 
knowledge, the increases in heart rates after intravenous administration seem to be 
less in rats and humans than in dogs (Szemeredi et al., 1989; Schafers et al., 1992; 
Sciberras et al., 1994; Pagel et al., 1998). This finding is in accordance with previous 
suggestions that canines would be more sensitive than humans to the action of 
drugs acting on vascular 2-adrenoceptors (Flacke et al., 1990; Bloor et al., 1992a 
and b). In any case, the cardiovascular outcome after intravenous MK-467 
administered alone might have detrimental effects in hypovolemic and/or vasodilated 
dogs (e.g. sepsis) due to the further increase in the vascular volume. As the dogs in 
this study were healthy and assumed normovolemic, unchanged central venous 
pressure would not necessarily have adequately reflected the systemic redistribution 
of blood or the remaining reserve capacitance of, for instance, either venous or 
splanchnic vasculature (Gelman 2008). On the other hand, the decrease in afterload 
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might be beneficial for some patient categories, such as in advanced chronic cardiac 
valvular disease, where blood regurgitation and congestion might be less with lower 
systemic vascular resistance (Atkins et al., 2009). However, further studies would be 
necessary to investigate the effects of MK-467 in dogs with various clinical 
cardiovascular conditions. 
   Moreover, in clinical anesthesia, the use of vasopressors is a fundamental 
necessity to correct severe hypotension (Chen et al., 2007; Rosati et al., 2007). As 
many of the vasopressors used produce their action by inducing vasoconstriction via 
the peripheral 1-adrenoceptors located in vascular smooth muscle, it would to be 
prudent to confirm that MK-467 does not significantly attenuate the efficacy of these 
drugs. Due to its relatively low 21 specificity, MK-467 might have some 
antagonistic activity at the 1-adrenoceptors, although in rats it was unable to inhibit 
aortic contraction induced by clonidine, an 2-adrenoceptor agonist with agonist 
activity at the 1-adrenoceptor (Iwanaga et al., 1998; Monteiro et al., 2007). Other 
theoretical complications such as the ‘epinephrine reversal syndrome’ (Kaul and 
Grewal, 1970; Hunyady and Johnson, 2006) seem very unlikely, as the use of 
adrenaline did not induce hypotension in dogs pre-treated with both MK-467 and 
dexmedetomidine (Hayashi et al., 1991). 
   The dose-dependent effect of MK-467 on dexmedetomidine-induced changes in 
heart rates, mean arterial pressure and cardiac index differed markedly from 
previous experiments with antimuscarinic drugs. In contrast to the tachycardia and 
severe hypertension observed in several studies that have included atropine and/or 
glycopyrrolate before or after either medetomidine or dexmedetomidine (Alibhai et 
al., 1996; Alvaides et al., 2008; Ko et al., 2001), heart rates and mean arterial 
pressures remained within acceptable limits with dexmedetomidine/MK-467. 
Furthermore, cardiac dysrhythmias were abolished with the higher dose ratios in the 
present study, and the cardiac index was better preserved by MK-467 than 
previously reported for both atropine and glycopyrrolate (Short 1991; Bloor et al., 
1992a; Congdon et al., 2011). Artificially preventing the cardiovascular system from 
adapting to any given afterload, e.g. by the administration of muscarinic antagonists, 
leads to non-physiological states where the Frank–Starling mechanism of 
ventricular–vascular coupling is overruled (Jacob and Kissling, 1989). Forced 
tachycardia against an increased afterload leads to an increased myocardial 
workload accompanied by a higher oxygen demand and consumption (Lemke et al., 
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1993; Alibhai et al., 1996; Sinclair et al., 2003). Acute or prolonged hypertension can 
also lead to circulatory disturbances followed by, for example, ocular lesions or 
cerebrovascular events (Wessmann et al., 2009; Leblanc et al., 2011).  Enouri et al. 
(2008) found little improvement from pre-treatment with glycopyrrolate, even when 
combined with MK-467, when compared to antagonist alone in dogs receiving 
medetomidine. While life-threatening bradycardia must obviously be addressed by 
any mean available, no indication for the routine addition of antimuscarinic drugs to 
2-adrenoceptor agonists was identified from the existing literature. It is probable that 
MK-467 would provide a more benign strategy to improve the cardiovascular 
performance of dogs sedated with either medetomidine or dexmedetomidine. 
6.3 Respiratory effects 
Dexmedetomidine decreased respiratory rates and induced a mild reduction in PaO2,
which is in accordance with previous studies (Vainio 1989; Nguyen et al., 1992; 
Kuusela et al., 2000 and 2001a). MK-467 was unable to prevent the slight decrease 
in PaO2 and elevations in P(A-a)O2 seen with every treatment including 
dexmedetomidine. If anything, PaO2 tended to be slightly more reduced by MK-467 
during the first 20 minutes after drug administration, although statistical significance 
between treatments was not reached. As PaCO2 tended to be higher with the 
treatments including the antagonist, a moderate increase in hypoventilation could 
explain the differences in PaO2 between treatments. On the other hand, respiratory 
rates were somewhat higher with all dexmedetomidine/MK-467 treatments early on. 
Thus, the differences in arterial gas tensions might be explained by a reduction in 
tidal and minute volumes when compared to dexmedetomidine alone. Actually, 
dexmedetomidine has been reported to enhance ventilation at very high doses (up to 
100 μg/kg IV) in conscious dogs, an effect which was already seen with the dose 
levels used in the present study (Nguyen et al., 1992). In any case, any increase in 
ventilatory drive was abolished or reversed by concurrent administration of propofol 
or isoflurane (Nguyen et al. 1992, Kuusela et al., 2001b and 2003).  
   However, it cannot be excluded that MK-467 either blunted a stimulatory or 
accentuated an inhibitory effect on respiration induced by dexmedetomidine in 
conscious dogs that were breathing room air. One possible explanation could be an 
imidazoline-receptor mediated increase in the venous admixture, as MK-467 does 
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not possess the necessary chemical structure to act as an antagonist at these 
receptors (Clineshmidt et al., 1988; Kamibayashi et al., 1995b). Ernsberger et al. 
(1998b) postulated that activation of imidazoline receptors in the carotid body of cats 
and rabbits facilitates chemosensory responses to hypoxemia, while 2-
adrenoceptors would inhibit this response. Thus, if such inhibitory effect was 
prevented by MK-467, the remaining stimulatory effect mediated by 
dexmedetomidine via imidazoline-linked chemoreceptors might explain the slight but 
consistent differences between treatments in this study. Sudden increases in SVR 
have also been associated with increased tidal and minute volumes without affecting 
respiratory rates in humans suffering from vagal syncope (Taneja et al., 2008). 
Furthermore, decreases in carotid body perfusion have been implicated as a 
potential mechanism behind a hyperpneic response (Nimbkar and Lateef, 2005). 
Consequently, the global hemodynamic changes induced by dexmedetomidine could 
also account for the differences in PaCO2 levels in the present study. 
   The mechanism behind reductions in PaO2 after dexmedetomidine administration 
remains unclear, and the findings of the present study are suggestive of a 
pathophysiology mediated by other than 2-adrenoceptors. Fortunately, as dogs are 
not very susceptible to 2-adrenoceptor agonist-mediated hypoxemia when 
compared, for instance, to small ruminants (Kästner 2006), the moderate decreases 
in PaO2 should not be of a major concern in healthy animals. Overall, however, more 
detailed in vitro and in vivo efforts are necessary to comprehensively evaluate the 
effect of dexmedetomidine on the ventilation/perfusion ratio in canines. In any case, 
dexmedetomidine is unlikely to induce severe hypoxemia in healthy dogs, and MK-
467 is as unlikely to improve pulmonary gas exchange in compromised animals. 
However, despite small differences in PaO2 between treatments, oxygen delivery 
was superior with treatments including MK-467 as a consequence of a significantly 
improved cardiac index when compared to dexmedetomidine alone. Arterial lactate 
concentrations were also higher without the antagonist, indicating reduced tissue 
perfusion. 
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6.4 Plasma drug concentrations 
6.4.1 Plasma concentrations of dexmedetomidine 
Plasma concentrations of dexmedetomidine administered alone were similar to 
previous reports, and levels that have been associated with profound sedation in 
dogs were achieved with all treatments (Kuusela et al., 2000). That said, MK-467 
markedly reduced the exposure to dexmedetomidine with each dose ratio, as 
described by the apparent decreases in AUC0-90. Differences in the cardiac index 
reported in study II also reflected the significant increase in volumes of distribution 
and clearance when compared to dexmedetomidine alone. A reduction in blood flow 
to peripheral vascular beds has been suggested to decrease the distribution of drugs 
that would otherwise be rapidly spread to tissues (De Paepe et al., 2002). 
Furthermore, in the present study, a large deviation in the earliest plasma 
concentrations was observed when dexmedetomidine was administered alone. As 
an explanation, the immediate distribution within the central compartment might have 
been incomplete, since the average cardiac output without MK-467 was reduced to 
less than the estimated circulating total blood volume per minute (Hahn et al., 1942). 
Curiously, the time when the maximum plasma concentration of detomidine, another 
2-adrenoceptor agonist, was observed in horses ranged from one to six minutes 
after intravenous administration (Grimsrud et al., 2009). Dexmedetomidine has also 
been shown to alter its own plasma concentrations in humans as a result of changes 
in cardiac output. However, the differences between the measured cardiac outputs 
and several target plasma concentrations were small, and as infusion regimens were 
used instead of bolus dosing, were likely more descriptive of changes in the 
elimination clearance (Dutta et al., 2000).  
   In the present study, the early effect of MK-467 was pronounced, while differences 
were less than obvious after the immediate distribution phase. While the short 
sampling time in study IV did not allow for proper comparisons of the elimination 
clearance rate between treatments, MK-467 did not seem to noticeably influence the 
later rate of decline of dexmedetomidine concentrations within the central 
compartment, as indicated by the similarity of the slopes between treatments. This 
finding would be consistent with previous suggestions concerning the importance of 
biotransformation in the elimination pathway (Salonen et al., 1989; Salonen and 
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Eloranta, 1990; Duhamel et al., 2010). Kaivosaari et al. (2002) showed a lower N-
glucuronidation rate in dog liver microsomes when compared to humans, which 
might further implicate hepatocellular phase II metabolic activity as the rate-limiting 
step in the terminal elimination rate of dexmedetomidine in healthy canines rather 
than the absolute degree of hepatic perfusion. 
   On the other hand, it would be inappropriate to assume that the clearance of 
dexmedetomidine would be unaffected by its negative effects on cardiovascular 
function. In fact, Salonen et al. (1995) postulated that atipamezole enhanced the 
clearance of medetomidine in dogs by restoring hepatic perfusion. The alteration 
between treatments in the disposition of dexmedetomidine in study IV could just as 
well have reflected differences in cardiac output and the consequent rate of hepatic 
clearance, which were most likely augmented by MK-467. However, 
contemporaneous increases in both the distribution (i.e. tissue perfusion) and 
metabolic clearance (i.e. hepatic perfusion) might best explain the lower plasma 
concentrations seen with dexmedetomidine/MK-467 throughout the sampling period. 
Importantly, and especially since only the parent compound concentrations were 
analyzed, it was not possible to determine the detailed relationship between liver 
blood flow and the intrinsic hepatic clearance of dexmedetomidine in dogs from the 
presently obtained results. 
   A pharmacokinetic model that incorporates the changes in cardiac output induced 
by dexmedetomidine has recently been introduced (Pypendop et al., 2012). While 
this model is based on data acquired from cats, parallel modeling would conceivably 
be valid for dogs as well. On the other hand, the pharmacokinetic behavior of 
dexmedetomidine seen with MK-467 in the present study would reduce the need for 
complex modeling, as the cardiovascular performance would remain unaffected.  
   In any case, the clinical consequence of the alterations in plasma concentrations in 
this study require further evaluation and would also necessitate detailed description 
of the pharmacokinetics of MK-467 in dogs, which was also beyond the scope of this 
current effort. Potential chemical interactions between the two molecules should also 
be evaluated. Nevertheless, the significant effect on the disposition of 
dexmedetomidine induced by MK-467 is unlikely to hinder more detailed 
pharmacokinetic-pharmacodynamic modeling of the combination in future studies. 
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6.4.2 Plasma concentrations of MK-467 
Novel information regarding the pharmacokinetics of MK-467 in dogs was obtained 
in study IV. While no efforts were made to assess the concentrations of MK-467 
within the CNS, the low volume of distribution confirms the hydrophilic nature of MK-
467, which supports its preference to remain within the central compartment after IV 
administration. Furthermore, dexmedetomidine did not noticeably influence the 
disposition of MK-467, which facilitates both the design of future efforts and the 
prediction of dose responses. The similar AUC0–90 achieved with the two higher 
doses of MK-467 might derive from moderate cardiovascular differences between 
the two treatments (i.e. differences in distribution and/or clearance), although the 
non-linear dose exposure should be confirmed with a more adequately designed 
pharmacokinetic study. 
6.5 Clinical sedation 
MK-467 did not have any apparent sedative or stimulatory effect, which would 
support its lack of effect within the canine CNS. Furthermore, the degree of clinical 
sedation induced by combinations of dexmedetomidine and MK-467 was 
bioequivalent with dexmedetomidine alone, at least when assessed according to the 
EMA guidelines. All treatments including the agonist led to moderate or deep 
sedation. However, as a reduction in the sedative effects with dexmedetomidine/MK-
467 treatments when compared to dexmedetomidine alone was observed, it cannot 
be claimed that the antagonist had no effect on the central effects of 
dexmedetomidine. Furthermore, the sensitivity of the composite sedation score 
applied in studies I and III in recognizing minor differences in the degree of sedation 
has not been properly evaluated. Consequently, the clinical significance of the 
differences found here should be evaluated and confirmed, if possible, by more 
objective means.  
   The lower plasma concentrations of dexmedetomidine attributed to MK-467 might 
have reduced the availability of the agonist drug in the CNS, thus potentially affecting 
the degree of sedation. However, radiolabeling studies and/or experiments focusing 
on drug concentration differences between plasma and the CNS should be 
conducted to confirm any significant effect of MK-467 on the central distribution of 
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dexmedetomidine (Lin, 2008). Should this prove to be the case, higher absolute 
doses of dexmedetomidine should be evaluated, as there is no reason why MK-467 
would not prevent the cardiovascular effects as long as suitable dose ratios are 
chosen. Moreover, despite the low volume of distribution detected in study IV, the 
peripheral selectivity of MK-467 has not been adequately confirmed in dogs, and it is 
therefore possible that some portion of the antagonist penetrated through the blood–
brain barrier and exhibited a mild antagonistic effect at the 2A-adrenoceptors within 
the canine CNS. 
   It is also worth considering that some pathological conditions might also impair the 
integrity of the canine BBB, such as chronic hypothyroidism, steroid responsive 
meningitis or trauma (Pancotto et al., 2010; Tipold and Schatzberg, 2010). Thus, the 
effects of MK-467 in the face of such pathologies might be unpredictable when 
compared to healthy animals. Furthermore, as the function of the permeability 
glycoprotein within the BBB can be inhibited by pharmacotherapy (e.g. 
ketoconazole) or affected by hereditary genetic conditions (e.g. ABCB1/MDR-1 
mutation in some dog breeds), further efforts are necessary to properly evaluate both 
the safety and efficacy of MK-467 in order to find potential deviations from the effects 
seen in this study (Dowling, 2006; Hugnet et al., 2007). It is currently not known 
whether MK-467 is a substrate for the canine permeability glycoprotein. 
   The recoveries after atipamezole were rapid and calm with both dexmedetomidine 
and dexmedetomidine/MK-467 in study I, although some residual sedation was 
observed 20 minutes after reversal when the dogs did not receive the peripheral 
antagonist. While this could be indicative of the lower achieved plasma 
concentrations of dexmedetomidine in the presence of MK-467, it might also imply 
greater central bioavailability of atipamezole as, coupled with better tissue delivery 
via the preserved hemodynamics, MK-467 could have competitively inhibited binding 
of the central reversal agent to the peripheral 2-adrenoceptors. It is also possible 
that any portion of MK-467 crossing the BBB might have acted in synergy with 
atipamezole. Nevertheless, residual sedation impairs the return to normal 
physiological function and thus, irrespective of the detailed mechanism of this 
observation, MK-467 might hasten complete recoveries after dexmedetomidine 
sedation in dogs. Overall, the degree of clinical sedation induced by 
dexmedetomidine was inhibited by MK-467 to such a small extent that the benefits 
from a markedly improved cardiovascular performance cannot be overruled. 
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6.6 Clinical implications and future prospects 
Concerns regarding the cardiovascular effects of 2-adrenoceptor agonists have 
previously prevented their use in compromised animals (Murrell and Hellebrekers, 
2005). Small doses of both medetomidine and dexmedetomidine have been shown 
to induce marked reductions in the cardiac index and the consequent oxygen 
delivery, proving these concerns valid. Prior experiments incorporating 
antimuscarinic drugs to counteract the characteristic bradycardia have repeatedly led 
to significant hypertension and increases in the myocardial workload, making this 
approach inappropriate. In contrast, MK-467, by dose-dependently reversing the 
peripheral 2-adrenoceptor-mediated vasoconstriction induced by either 
medetomidine or dexmedetomidine, could ensure a more physiological 
cardiovascular function while allowing for the sedative action of either agonist drug. 
In essence, based on the present results, simultaneous administration of MK-467 
would potentially increase the clinical safety margin of 2-adrenoceptor agonists. 
   Peripheral 2-adrenoceptors may have a role in mediating some of the 
antinociceptive properties of dexmedetomidine (Poree et al., 1998; Tomic et al., 
2007; Al-Metwalli et al., 2008). Consequently, MK-467 might impede the quality of 
analgesia achieved with 2-adrenoceptor agonists. Therefore, experimental and 
clinical efforts would be necessary to evaluate any potentially negative influence of 
MK-467 on the efficacy of both medetomidine and dexmedetomidine in alleviating 
pain, especially in an acute perioperative setting due to the nature of use of 2-
adrenoceptor agonists in clinical veterinary medicine. A possible attenuating effect of 
MK-467 on the synergy between, for instance, opioids and 2-adrenoceptor agonists 
should also be evaluated in clinical patients (Gursoy et al., 2011). 
   Many recent efforts in humans have been made to describe the significance of 
genetic variation in the haplotype expression of different 2-adrenoceptor subtypes, 
and the potential consequence for the sensitivity to 2-adrenoceptor agonists 
(Muszkat et al., 2005 and 2010; Kurnik et al., 2006 and 2011). While numerous novel 
variants in genes encoding the different 2-adrenoceptors of healthy volunteers have 
been identified, their role in mediating a varying peripheral cardiovascular sensitivity 
to dexmedetomidine remains to be elucidated. The canine pharmacogenetics of 2-
adrenoceptors remains an undiscovered field of study to date, with many genetically 
condensed breeds potentially facilitating the discovery of clinically relevant haplotype 
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variation. Presently, 2-adrenoceptor subtype-specific drugs are commercially 
unavailable. The constantly accumulating knowledge of structural differences 
between receptor subtypes mediating distinct pharmacological effects might guide 
research and development towards more specific drugs, free of undesirable side or 
adverse effects. 
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7. Conclusions 
1) MK-467 dose dependently prevented or attenuated the early hemodynamic 
changes induced by dexmedetomidine in healthy, conscious dogs. Simultaneous 
intravenous administration of the two drugs proved efficacious and reliable, yielding 
steady levels of oxygen delivery throughout the studies. 
2) MK-467 reduced the plasma concentrations of dexmedetomidine, which might 
explain the small differences seen in the degree of clinical sedation.  
3) Besides a transient sinus tachycardia (accompanied by a reduction in systemic 
vascular resistance), no clinically observable adverse effect was seen when MK-467 
was administered alone. 
4) MK-467 decreased the intensity of clinical sedation by dexmedetomidine. 
Atipamezole successfully reversed the clinical sedation induced by 
dexmedetomidine/MK-467.  
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